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Abstract
Merkel cell polyomavirus (MCPyV) is the first polyomavirus clearly associated with a human
cancer, i.e. the Merkel cell carcinoma (MCC). Polyomaviruses are small naked DNA viruses
that induce a robust polyclonal antibody response against the major capsid protein (VP1).
However, the polyomavirus VP1 capsid protein epitopes have not been identified to date.
The aim of this study was to identify the neutralizing epitopes of the MCPyV capsid. For this
goal, four VP1 mutants were generated by insertional mutagenesis in the BC, DE, EF and
HI loops between amino acids 88-89, 150-151, 189-190, and 296-297, respectively. The re-
activity of these mutants and wild-type VLPs was then investigated with anti-VP1 monoclo-
nal antibodies and anti-MCPyV positive human sera. The findings together suggest that
immunodominant conformational neutralizing epitopes are present at the surface of the
MCPyV VLPs and are clustered within BC and EF loops.
Introduction
Polyomaviruses are known to infect mammals and birds. Thirteen human polyomavirus have
been identified to date including BKPyV [1], JCPyV [2], KIPyV [3], WUPyV [4], Merkel cell
polyomavirus (MCPyV) [5], HPyV6 and HPyV7 [6], TSPyV [7], HPyV9 [8], MWPyV [9–11],
STLPyV [12], HPyV12 [13] and NJPyV [14]. MCPyV has been associated with Merkel cell car-
cinoma (MCC) and is now recognized as a 2A carcinogen by IARC [15].
MCC is a relatively rare but aggressive skin cancer with a mortality rate higher than melano-
ma. MCC is rarely observed in people younger than 50 years of age, and the risk of developing
PLOSONE | DOI:10.1371/journal.pone.0121751 March 26, 2015 1 / 13
a11111
OPEN ACCESS
Citation: Fleury MJJ, Nicol JTJ, Samimi M, Arnold F,
Cazal R, Ballaire R, et al. (2015) Identification of the
Neutralizing Epitopes of Merkel Cell Polyomavirus
Major Capsid Protein within the BC and EF Surface
Loops. PLoS ONE 10(3): e0121751. doi:10.1371/
journal.pone.0121751
Academic Editor: Nicholas J Mantis, New York State
Dept. Health, UNITED STATES
Received: December 24, 2014
Accepted: February 4, 2015
Published: March 26, 2015
Copyright: © 2015 Fleury et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: Data are all included in
the paper.
Funding: NC and JTJN were supported by a
Doctoral grant from INSERM/Région Centre and
Région Centre, respectively. Grants from the Ligue
Contre le Cancer to PC (2009-2010) and AT (2010-
2011). The funders had no role in study design, data
collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
this cancer increases with age, immunodeficiency and sun exposure [16–18]. MCPyV was
identified in 2008 as the causative agent of the majority of MCC [5,19]. Viral particles are not
produced in MCC tumor cells [20,21] and the specific cells in which MCPyV infectious viral
particles are produced have not yet been identified.
Polyomaviruses are small naked DNA viruses and their icosahedral capsid of about 45 nm
in diameter is constituted of VP1, VP2 and VP3 proteins, and encapsidate a double-stranded
circular DNA of about 5 kbp. The minor capsid proteins VP2 and VP3 are sequestered within
the shell of the capsid formed by the VP1 protein [22]. As for SV40 polyomavirus, each VP1
monomer is composed of two antiparallel b-sheets, which together form a b-sandwich with
jelly-roll topology [23]. The two sheets consist of strands that support extensive loops, named
BC, DE, EF and HI, exposed at the surface and sides of the pentamer. These loops are the most
variable parts of VP1 sequences.
Serological studies have shown that, as observed for other human polyomaviruses, most
adults have had prior exposure to MCPyV [20,24–29]. The nature of the epitopes that elicit an-
tibodies against the viral capsid is unknown. Immunization of mice with MCPyV VP1 virus-
like particles (VLPs) induces high titers of antibodies [20,25] which have been shown to be
neutralizing [20] as anti-MCPyV VP1 monoclonal antibodies [30].
The antibody response against small naked DNA virus is typically generated against epi-
topes exposed at the surface of the VLPs [31–34]. However, the nature of the epitopes that elicit
antibodies to polyomavirus capsid proteins is largely unknown except for SV40, the epitopes of
which have been mapped using monoclonal antibodies and replicative mutants in the BC and
EF loops [35].
In order to identify the major MCPyV VP1 conformational epitopes, we investigated the re-
activity of wild-type and four VP1 protein insertional mutants against a panel of anti-MCPyV
VP1 monoclonal antibodies (mAbs) and anti-MCPyV positive human sera.
Materials and Methods
Generation and characterization of MCPyV VP1 mutants
In addition to MCPyV [21,25], SV40 [36], BKPyV [37], LPyV [25], HPyV6, HPyV7, HPyV9
and TSPyV [38] VP1 VLPs, four MCPyV VP1 insertional mutants were also produced in insect
cells using recombinant baculoviruses. For this purpose, MCPyV VP1 gene mutants were gen-
erated by SOE-PCR using the MKT21 sequence as template (FM864207.1). The StreptagII
motif (WSHPQFEK) coding sequence was inserted in the predicted surface exposed loops
(after S88 of BC, after H150 of DE, after T189 of EF, after T296 of HI) using the MKT21 se-
quence model generated by Swiss-Model (http://swissmodel.expasy.org/) and the 1SVA pdb
file as template. PCR fragments representing the 5’ and 3’ parts of the VP1 gene were obtained
in an initial step of 6 cycles (94°C 30s, 50°C 30s, 72°C 2 min) using 5’fullVP1 and 3’ loop prim-
er and 5’ loop primer and 3’ full VP1, respectively (Table 1). Then 5’ and 3’ fragments were as-
sembled in a 6 cycle second PCR step (94°C 30 s, 50°C 30 s, 72°C 2 min 30 s). PCR products
were cloned by TA cloning into the pCR2.1TOPO plasmid (Invitrogen, Fischer, Illkirch,
France). The presence of the StreptagII motif sequence and absence of unwanted mutagenesis
was verified by sequencing (MWG Biotech, Ebersberg, Germany). Modified VP1 genes were
then cloned between the BamHI and HindIII restriction sites of the pFastBac1 plasmid (Invi-
trogen) to generate the different recombinant baculoviruses. Recombinant baculoviruses were
generated using the Bac to Bac technology (Invitrogen).
For the production of VLPs, Sf21 insect cells maintained in SF900II serum-free medium
(Invitrogen) at 27°C were infected with the different recombinant baculoviruses. VLPs were
purified as described previously and the presence of VLPs was analyzed by transmission
MCPyV Capsid Neutralizing Epitopes
PLOS ONE | DOI:10.1371/journal.pone.0121751 March 26, 2015 2 / 13
electron microscopy [25]. Exposure of the StreptagII motif was searched by ELISA using a
mouse anti-StreptagII monoclonal antibody conjugated to HRP (Novagen, VWR, Strasbourg,
France). Microplates (Maxisorp, Nunc) were coated with 200 ng per well of VLPs or PBS and
incubated at 4°C overnight. Wells were then blocked with PBS supplemented with 1% FCS for
1 h at 37°C. Duplicate wells (two tests and one control) were incubated with anti-Strepta-
gII-HRP monoclonal antibody diluted 1:1000 in dilution buffer (PBS 5X, 1% Tween, 10% FCS)
for 1 h at 37°C. After four washes, 100 μl of a solution containing 0.4 mg/ml o-phenylene-di-
amine and 0.03% hydrogen peroxide in 25 mM sodium citrate and 50 mMNa2HPO4 was
added. The reaction was stopped after 30 min with 100 μl 4 N H2SO4 and absorbance was read
at 490 nm. A positive result was recorded when the difference in OD between test and control
wells was greater than 0.20. The results are the means of three determinations.
Production of monoclonal antibodies
Six week-old female Balb/C mice (IFFACredo, St. Germain l’Arbresle, France) were immunized
by intrapodal injection with purified MCC350 aggregates or MKT21 VLPs (50 μg) emulsified
in Quil A (50 μg), conducted as previously described with minor modifications [39]. After 12
days, each mouse was boosted with the same preparation. Three days later, mice were sacrificed
and popliteal lymph nodes were collected. Lymphocytes were collected by perfusing the lymph
node with RPMI 1640-Glutamax medium (Invitrogen). Cells were washed once in RPMI and
centrifuged at 300 g for 5 min and mixed with Sp2/O myeloma cells at a ratio of 1:5. Cells were
then collected by centrifugation at 300 g for 5 min and fusions were performed as previously
described [40]. Hybridoma culture supernatants were screened by ELISA for antibody reactivi-
ty to intact MCPyV VP1 VLPs and to dissociated VLPs obtained by treatment with 0.1 M car-
bonate buffer (pH 10.6) and 0.01 M dithiothreitol (DTT) in PBS for 30 min at 37°C.
Subcloning was performed by end-point dilutions in 96-well plates and reactive subclones were
isotyped using the mouse mAb isotyping kit according to the recommended procedure
(Sigma-Aldrich). To characterize the type specificity of these mAbs, ELISAs were performed
with MCPyV, SV40, LPyV, HPyV6, HPyV7, HPyV9, TSPyV and BKPyV VP1 VLPs. For
ELISA, microplates (Maxisorp, Nunc) were coated with 200 ng of VLPs per well of and incu-
bated at 4°C overnight and then blocked with PBS supplemented with 1% FCS for 1 h at 37°C.
Table 1. Sequence of primers used for generation of MCPyV VP1mutantsa
Name 5’!3’ Restriction site
5’ full VP1 GGATCCCCTGAATTACAAGTAATTGAAGATGGCACC BamHI
3’ full VP1 AAGCTTCTGAATAGGAATGCATGAAATAATTCTCAT HindIII
5’ BC loop TGGAGCCATCCGCAATTTGAAAAGTCTCCAGATCAGCCCATCAAGG
3’ BC loop CTTTTCAAATTGCGGATGGCTCCATGATCCCTTTGGCTGCAGGTCATAAG
5’ DE loop TGGAGCCATCCGCAATTTGAAAAGGATTACGGTGCTGGTATTCC
3’ DE loop CTTTTCAAATTGCGGATGGCTCCAATGAACTCTTTTCATGTCCC
5’ EF loop TGGAGCCATCCGCAATTTGAAAAGACAAATGGTGGGCCTATTACAATTG
3’ EF loop CTTTTCAAATTGCGGATGGCTCCAAGTTTTTGGATACTCAGTCTGGTAATC
5’ HI loop TGGAGCCATCCGCAATTTGAAAAGAGTGGAAAAATGGCTCTTCATGGG
3’ HI loop CTTTTCAAATTGCGGATGGCTCCAGGTTTTAAACAGAAACCCCACTATG
a Restriction site sequences are italicized
doi:10.1371/journal.pone.0121751.t001
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Duplicate wells (two tests and one control) were incubated with hybridoma culture superna-
tant diluted 1:3 in dilution buffer (PBS 5X, 1% Tween, 10% FCS) for 1 h at 37°C. The plates
were washed four times and probed with peroxidase-conjugated goat anti-mouse Ig Fc
(Sigma-Aldrich; 1:5,000 dilution) for 1 h at 37°C. After four washes, colorimetric revelation
was performed as above. A positive result was scored when the difference in OD between test
and control wells was greater than 0.20. The data presented are the means of
three determinations.
All animal procedures were performed according to approved protocols and in accordance
with the recommendations for the proper use and care of laboratory animals, and experiments
were approved by the Regional Animal Ethics Committee (Approval ID CL2006-048, Comité
Régional d'Ethique en Matière d'Expérimentaion Animale Centre-Limousin).
Generation of MCPyV pseudovirions and detection of anti-MCPyV
neutralizing antibodies
MCPyV pseudovirions were produced in human embryonic kidney-derived 293FT cells. The
293FT cell line (Invitrogen) is a fast growing variant of the 293 cell line that stably expresses
SV40 TAg and the neomycin resistance gene from pCMVPORT6AT.neo plasmid. 293FT cells
were grown in Dulbecco’s modified Eagle’s Medium, supplemented as above, plus 1% non-es-
sential amino acids and 500 mg/ml G418 (Invitrogen). Cell lines were grown at 37°C in a hu-
midified atmosphere with 5% CO2. These cells were co-tranfected with expression plasmids
carrying codon-modified versions of MCPyV VP1 (pwM) and VP2 genes (ph2m) of MCPyV
isolate 339 [41] (generous gift of Chris Buck, NCI) and the pGL4 plasmid as luciferase expres-
sion reporter (Promega). Transfected cells were then cultured for 3 days in complete Dulbec-
co’s modified Eagle’s medium (Invitrogen, DMEM supplemented with 10% FCS, 100 IU/ml
penicillin, 100 μg/ml streptomycin and 250 μg/ml hygromycin B). Pseudovirions present in the
nuclear fraction of 293FT (MCPyV PsV stock) were titered by measuring their end-point lucif-
erase gene transduction capacities on COS-7 cells (African green monkey kidney cells, ATCC
CRL-1651). For the detection of neutralizing antibodies, COS-7 cells (104/well) were seeded in
96-well plates (TPP, Dutscher, Brumath, France). COS-7 cells were grown in Dulbecco’s modi-
fied Eagle’s Medium (Invitrogen) supplemented with 10% heat-inactivated fetal calf serum
(FCS), 100 IU/ml penicillin, and 100 μg/ml streptomycin and 1 mM sodium pyruvate. After
24h incubation at 37°C, cells were washed twice before addition of pseudovirion/antibody mix-
ture. The amount of pseudovirions was adjusted to obtain a relative luciferase activity of 0.2
RLU (Luminoskan Ascent, Thermo Scientific, Courtaboeuf, France). Twenty five microliters of
diluted pseudovirions were mixed with 25 μl of hybridoma supernatants at a final dilution of
1:3 in incomplete DMEMmedium or human sera at a final dilution of 1:1000. After 1h incuba-
tion at 37°C, the mixture was added to the wells and plates were incubated for 3 h at 37°C.
Then, the mixture was removed, 100 μl of DMEM-FCS were added and, after incubation at
37°C for 48 h, the luciferase gene expression was measured (Luciferase reporter gene assay with
constant light signal, Roche Molecular Biochemical, Meylan, France). The results were express-
ed as the percentage of inhibition of luciferase activity [40,42]. The data presented are the
means of 3 determinations performed in duplicate. Antibodies were considered to be neutraliz-
ing for inhibition greater than 80%.
For investigation of post-attachment neutralization, pseudovirions were bound to cells for 1
h at 4°C. Unbound virions were removed by washing cells with serum-free DMEM and then
antibodies diluted 1:3 in DMEM-FCS were added to a total volume of 50 μl. After 1h at 37°C,
the antibodies were removed, then 100 μl of DMEM-FCS were added and after incubation for
48 h the luciferase activity was measure as above.
MCPyV Capsid Neutralizing Epitopes
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Reactivity of MCPyV mAbs and human antibodies against MCPyV VLP
mutants
In order to locate the epitopes of the MCPyV VP1, the reactivity of mAbs and human antibod-
ies was analyzed using the MCPyV wt VP1 VLPs and the four mutants with insertion within
the BC, DE, EF and HI VP1 loops. ELISAs were performed as described above for this purpose.
Hybridoma culture supernatants were diluted 1:3 and human anti-MCPyV positive sera were
diluted 1:1000 in dilution buffer (PBS 5X, 1% Tween, 10% FCS) for 1 h at 37°C. Secondary anti-
bodies, peroxidase-conjugated goat anti-mouse Ig Fc and goat anti-human Ig Fc, were diluted
1:5,000 and 1:10,000 (Sigma-Aldrich), respectively. A positive result was recorded when the
difference in OD between test and control wells was greater than 0.2. The results are presented
as relative binding defined as the reactivity of mAb or human serum to mutant VLPs divided
by the reactivity of the same mAb or human serum observed with wild-type VLPs. This calcu-
lation was performed separately for each monoclonal antibody. The data presented are the
means of three determinations.
Monoclonal antibodies, polyclonal antibodies and human sera
A pool of serum from mice immunized with MCPyV MKT21 VLPs was used to evaluate cross-
reactivity among polyomaviruses and to validate the neutralization assay with MCPyV pseudo-
virions [25].
The type-specific anti-BKV mAb BKPyV-6A2 and anti-SV40 mAb SV40-10C5 produced
previously were also investigated for their capacity to bind to MCPyV VLPs (unpublished
data).
Ten human sera were obtained from MCC patients from the Dermatology Department of
Tours University Hospital (Tours, France)[21]. The protocol had been approved by the Comité
de Protection des Personnes, Tours-Région centre Ouest1 (ID: 2009-A01056-51).
Results
Generation of MCPyV VP1 insertional mutants and anti-MCPyV VP1
monoclonal antibodies
Generation of the insertion mutant of the major capsid protein has been shown to be a valid
approach to identify major conformational epitopes located on external antigenic loops
[43,44]. The published cristal structure of MCPyV confirmed our insertion sites at the tip of
BC, DE, EF and HI loops [23].
VP1-StreptagII insertion mutants were expressed using recombinant baculoviruses and pu-
rified from insect cell nuclei using isopycnic banding in CsCl gradient. Fractions with a density
around 1.272 g/ml presented a protein of 45 kDa (data not shown).
Electron microscopy observation of these fractions indicated that the VP1 protein of the
four mutants assembled into VLPs. However, DE, EF and HI VP1 mutants were more irregular
in shape and size than the BC VP1 mutant which was indistinguishable from wt VLPs (Fig. 1).
Exposure of the StreptagII motif at the surface of native mutant VLPs was confirmed for the
four mutants using an anti-StreptagII monoclonal antibody (data not shown).
Anti-MCPyV VP1 mAbs were generated using both MCC350 VP1 which have been shown
not to self-assemble into VLPs but only to form VP1 aggregates and MKT21 VP1 which self-
assembled into VLPs [25].
Sixty-five MCC350 hybridoma clones were generated, of which seven anti-VP1 secreting
hybridomas were characterized. In addition, sixty-nine hybridomas were generated against
MKT21 VP1 that self-assembled into VLPs, of which seven anti-VP1 secreting hybridomas
MCPyV Capsid Neutralizing Epitopes
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were characterized. Overall, twelve of these mAbs were IgG and two anti-MKT21 VLPs were
IgM (MKT21-3D2 and MKT21-3D3) (Table 2).
Characterization of anti-MCPyV VP1 monoclonal antibodies
The reactivity of the 14 anti-VP1 mAbs was investigated against intact and disrupted MKT21
VLPs. Antibodies reacting with intact but not disrupted VLPs were considered to be directed
against conformational epitopes located on the exposed surface of the viral capsid. Persistent
reactivity after disruption of the VLPs was interpreted as evidence of exposed linear epitopes at
the surface of the viral capsid. In the case of reactivity only to disrupted VLPs, this was taken as
evidence of buried linear epitopes. All the mAbs generated with MCC350 VP1 recognized bur-
ied linear epitopes. In contrast, all mAbs generated using MKT21 VLPs bound to conforma-
tional epitopes (Table 2).
Cross-reactivity of the seven conformation-dependent mAbs was investigated with other
human polyomavirus VP1 VLPs (SV40, LPyV, HPyV6, HPyV7, HPyV9, TSPyV and BKPyV).
None of them exhibited cross-reactivity. It should be noted that two previously generated
monoclonal antibodies, BKPyV-6A2 and SV40-10C5 mAbs, were also type-specific and con-
formation-dependent (Table 2).
The anti-MKT21 monoclonal antibodies were also able to neutralize MCPyV pseudovirions
in contrast to the seven antibodies generated against MCC350 VP1. As our aim was to identify
conformational neutralizing epitopes, the subsequent experiments were performed only with
the MKT21 derived mAbs.
Fig 1. MCPyV VP1 insertional mutants BC, DE, EF and HI. A)MCPyV surface exposed loops model generated using the MKT21 sequence with the VP1
structure information of MCPyV w162 strain (4FMG pdb file) by Swiss-Model. The StreptagII motif (WSHPQFEK) coding sequence was inserted into each
predicted surface exposed loop, after S88 of BC, after H150 of DE, after T189 of EF and after T296 of HI to generate four insertional mutants, BC, DE, EF and
HI, respectively. B)MCPyV VP1mutant particles observed by transmission electron microscopy after recombinant baculovirus expression and CsCl
gradient purification.
doi:10.1371/journal.pone.0121751.g001
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To determine whether the neutralization took place before or after attachment of the pseu-
dovirions to cells the seven neutralizing mAbs were added pre and post attachment and then
the reduction of transduction efficiency was determined. Experiments dichotomized the neu-
tralizing feature of the mAbs. MKT21-1D3, MKT21-1D4, and MKT21-5D2 neutralized pseu-
dovirions before their attachment to cells, whereas MKT21-1D1, MKT21-3D2, MKT21-3D3,
and MKT21-6A6 mAbs neutralized the pseudovirions after cell binding (Table 2, Fig. 2).
Location of MCPyV VP1 neutralizing immunodominant epitopes
The reactivity of the five mAbs exhibiting the highest neutralizing activity (MKT21-1D3,
MKT21-1D4, MKT21-3D2, MKT21-3D3 and MKT21-5D2) was evaluated against wild type
and the four MCPyV VP1 mutants (Fig. 3). The results indicated that insertion of heterologous
sequences into the DE and HI loops did not affect reactivity of any of the five mAbs investigat-
ed, with the exception of the MKT21-1D3 mAb where a strong reduction in reactivity observed
against a DE mutant. In contrast, the reactivity of the five mAbs was dramatically reduced with
the EF mutant. The reactivity of three mAbs, MKT21-1D4, MKT21-3D2 and MKT21-3D3,
was dramatically reduced with the BC mutant, but only a moderate reduction in reactivity was
observed with MKT21-1D3 and MKT21-5D2 mAbs.
In addition, the reactivity of the four mutants against ten anti-MCPyV positive human sera
was also evaluated. The neutralizing capacity of all the 10 human sera was first revealed using
the MCPyV pseudovirions (data not shown). Reactivity of all the human sera investigated was
dramatically reduced when tested against the EF loop insertion mutant and to a lesser extent
against the HI and BC mutants (Fig. 4).
Discussion
The strategy adopted to map immuno-dominant epitopes of the MCPyV VP1 capsid protein is
based on the assumption that the hypervariable loops at the capsomer surface contain
Table 2. Characteristics of 14 anti-MCPyVmAbs produced with VP1 fromMCC350 and MKT21 strains. BL, buried linear, C, conformational.
Name Ig isotype Type of epitope PyV Type speciﬁcity Neutralization
MCC350-A1B IgG2a BL ND -
MCC350-D5D IgG3 BL ND -
MCC350-B4A IgG3 BL ND -
MCC350-D1D IgG3 BL ND -
MCC350-C1A IgG2a BL ND -
MCC350-B1C IgG3 BL ND -
MCC350-B6B IgG3 BL ND -
MKT21-1D1 IgG3 C MCPyV +
MKT21-1D3 IgG3 C MCPyV +
MKT21-1D4 IgG2a C MCPyV +
MKT21-3D2 IgM C MCPyV +
MKT21-3D3 IgM C MCPyV +
MKT21-5D2 IgG2a C MCPyV +
MKT21-6A6 IgG3 C MCPyV +
Anti-BKPyV ND C BKPyV ND
Anti-SV40 ND C SV40 ND
MKT21 polyclonal ND ND MCPyV, SV40, LPyV, BKPyV +
doi:10.1371/journal.pone.0121751.t002
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Fig 2. Monoclonal antibodies neutralization mechanism after pre (black) or post (white) MCPyV
pseudovirions attachment. For the detection of neutralizing antibodies, COS-7 cells (104/well) and MCPyV
luciferase pseudovirions (0.2 RLU) were used. For the pre attachment determination, pseudovirions were
mixed with monoclonal antibodies supernatants diluted 1:3 during 1 h and then added to the cells for 3 h at
37°C. The mixture was removed and 100 μl of DMEM-FCS were added. For investigation of post-attachment
neutralization, pseudovirions were bound to cells for 1 h at 4°C. Unbound virions were removed and then
antibodies diluted 1:3 were added during 1h. The antibodies were removed and 100 μl of DMEM-FCSwere
added. After incubation for 48 h at 37°C the luciferase activity was measure. The results were expressed as
the percentage of inhibition of luciferase activity. The data presented are the means of three determinations
performed in duplicate (+/- SEM).
doi:10.1371/journal.pone.0121751.g002
Fig 3. ELISA reactivity of MCPyVmonoclonal antibodies against MCPyV insertional mutants BC, DE, EF and HI. In order to characterize the epitopes
of the MCPyV VP1, the reactivity of mAbs was analyzed using the MCPyV wt VP1 VLPs and the four mutants with insertion within the BC, DE, EF and HI VP1
loops. ELISAs were performed using hybridoma culture supernatants diluted 1:3. The results are presented as relative binding defined as the reactivity of
mAb to mutant VLPs divided by the reactivity of the same mAb observed with wild-type VLPs. The data presented are the means of three determinations (+/-
SEM).
doi:10.1371/journal.pone.0121751.g003
MCPyV Capsid Neutralizing Epitopes
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conformational neutralizing epitopes, and that insertion of small amino acid sequences abro-
gates antibody binding, similarly to the approach used for mapping conformational epitopes of
papillomaviruses and other polyomaviruses [31,33,43,45]. Insertion sites were initially deter-
mined by using an MCPyV VP1 MKT21 model constructed using Swiss model and SV40 VP1
cristallographic data as template (1SVA). The MCPyV VP1 w162 strain crystallographic data
were then available [23], and no major variation in the loops were observed between the experi-
mental and predicted models.
As observed for other polyomaviruses and papillomaviruses, insertion of short peptide se-
quences within the hypervariable loops did not dramatically alter the structure of the VLPs
[43,46]. VLPs derived from DE, EF and HI mutants exhibited a lower rate of T = 7 symmetry
VLPs associated with the presence of smaller VLPs. However, this heterogeneity is also ob-
served in wild type VLPs from MWPyV, HPyV6, HPyV9 and TSPyV [28,38].
In order to characterize the antigenic region of the MCPyV capsid, a panel of anti-VP1
mAbs was produced. The mAbs produced using MCC350 VP1 recognized only buried linear
epitopes, possibly explained by the fact that this protein did not assemble into VLPs [25]. All
mAbs developed against MKT21 VP1 were conformation-dependent and type-specific. This
was also observed by Pastrana et al. using VLPs derived from the MCC 339 sequence [30]. It
could be noticed that our panel is less rich in IgM clones, probably due to the fact that our im-
munization schedule included a booster dose.
All the conformation-dependent mAbs exhibited neutralizing activity against MCPyV pseu-
dovirions, confirming the findings of Pastrana et al. [30], and similar to those of Randhawa
et al. with BKPyV [47]. Pre- and post-attachment neutralization experiments indicated that
three out of the seven mAbs did not retain their neutralizing activity when added after
Fig 4. ELISA reactivity of 10 neutralizing anti-MCPyV positive human sera (MCC patients) against MCPyV insertional mutants BC, DE, EF and HI. In
order to characterize the epitopes of the MCPyV VP1, the reactivity of the human sera was analyzed from ten patients using the MCPyV wt VP1 VLPs and
the four mutants with insertion within the BC, DE, EF and HI VP1 loops. ELISAs were performed using neutralizing anti-MCPyV positive human sera diluted
1:1000. The results are presented as relative binding defined as the reactivity of human serum to mutant VLPs divided by the reactivity of the same human
serum observed with wild-type VLPs. The data presented are the means of three determinations (+/- SEM).
doi:10.1371/journal.pone.0121751.g004
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attachment. This suggests a conformational change of the capsid that occurred after the bind-
ing of the viral particles to a primary cell receptor, as observed for papillomaviruses [34,48–50].
Using MCPyV-specific mAbs and the VP1 insertion mutants allowed us to identify two
immunodominant epitopes within the BC and EF loops. The determinants of a conformational
epitope may be non-contiguous along a polypeptide sequence and occur in spatial proximity
only when the protein is folded. The finding that the two VP1 surface loops BC and EF contrib-
uted to the immunodominant neutralizing epitope of MCPyV is consistent with the findings of
Murata et al. [35] identifying neutralization epitopes of SV40 on the same hypervariable loops.
The presence of a conformational epitope on the BC loop has also been reported for mPyV
[46,51], and suggested for BKPyV, since serological subtypes are determined by mutations
within the BC loop [52]. Neutralizing antibodies presumably target functional domains on the
capsid domains. It was previously shown that sialylated glycans can act as primary receptors
for MCPyV [53] and that the binding to sialic acid was attributed to amino acids located on the
BC loop [23]. These results together suggest that the BC loop plays a key role in virus entry and
is the main target for immune response against MCPyV.
Analysis of the reactivity of the MCC patient sera with the four MCPyV mutants indicated
that the BC and HI mutants were less reactive to serum from some patients whereas the EF
mutant was poorly recognized by all MCC patient sera. These findings suggested that a major
antigenic region is located within the EF loop as did those obtained with
monoclonal antibodies.
In conclusion, our findings indicate the existence of type-specific conformational neutraliz-
ing epitopes on the MCPyV VP1 capsid on BC and EF loops, in agreement with the involve-
ment of at least the BC loop in cell binding. In addition, neutralization was observed with some
of the mAbs only before cell binding, suggesting a conformational change in the pseudovirions
before cell entry, as observed for Papillomaviruses [40,48].
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